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268 The Journal of Thoracic and Cardbjective: We have recently developed a thrombin-free fibrin-coated vascular
rosthesis that has a high performance rate in producing graft antithrombogenicity.
e hypothesized that autologous, compared with xenologous, fibrin coatings could
mprove the antithrombogenicity of grafts by reducing immunologic response.
ethods: Autologous fibrin-coated vascular prostheses and/or xenologous fibrin-
oated vascular prostheses (internal diameter, 2 mm; length, 2.5 cm) were implanted
n the bilateral carotid arteries of 50 Japanese white rabbits. They were classified
nto 2 groups by the selection of grafts in the individual: group I (autologous
brin-coated vascular prosthesis and xenologous fibrin-coated vascular prosthesis);
nd group II (group IIa: both autologous fibrin-coated vascular prostheses, or group
Ix: both xenologous fibrin-coated vascular prostheses). During a maximum of 180
ays after implantation, we evaluated the thrombotic, inflammatory, and immuno-
ogic responses associated with both types of graft.
esults: All grafts were patent at each end point. In group I, both platelet deposition
nd anti-graft antibodies in autologous fibrin-coated vascular prostheses were sig-
ificantly less than those in xenologous fibrin-coated vascular prostheses until
ostoperative day 30. At postoperative day 10, there were significantly fewer
D45-positive infiltrating cells in autologous fibrin-coated vascular prostheses, and
ntercellular adhesion molecule-1, vascular cell adhesion molecule-1, and nuclear
actor-kappa B expression in autologous fibrin-coated vascular prostheses were less
han those in xenologous fibrin-coated vascular prostheses. The neointimal hyper-
lasia in autologous fibrin-coated vascular prostheses was significantly decreased at
ostoperative day 180. In group II, serial changes of serum levels of immunoglob-
lin M, immunoglobulin G, interleukin-1, and tissue-type plasminogen activator/
lasminogen activator inhibitor-1 ratio in autologous fibrin-coated vascular pros-
heses were significantly less than those in xenologous fibrin-coated vascular
rostheses. In both grafts, platelet deposition significantly correlated with serum
mmunoglobulin G level and tissue-type plasminogen activator/plasminogen acti-
ator inhibitor-1 ratio.
onclusion: These findings suggest that autologous fibrin coating in thrombin-free
brin-coated vascular prostheses improve antithrombogenicity by reducing immu-
ologic response and have a potential for clinical use in hybrid small-caliber
ascular grafts.
n the development of small-caliber vascular prostheses, antithrombogenicity
plays a decisive role in the graft patency.1 Recently, the search for an ideal
prosthetic vascular graft has evolved from the development of inert, passive
aterials to the creation of active biomaterials that induce beneficial graft-tissue
nteraction. The principles of tissue engineering have elicited some encouraging
esults in various laboratories.2,3 However, these techniques require weeks of
iovascular Surgery ● May 2007
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ETulture before use, because of the large number of cells
eeded for seeding, and cause a problem because of the
elamination of seeded cells by hemodynamic shear stress4
nd disruption of them by activated leukocytes5 in the acute
hase of implantation.
Our concept of the hybridization of vascular prosthe-
es was based on a combination of biomaterial and self-
egenerative principles. A recent study reported that fibrin
atrix might have many advantages, such as promoting cell
igration and matrix synthesis and reducing toxic degrada-
ion and inflammatory reaction.6 Because of its biocompat-
bility, fibrin matrix is also thought to interact with tissues
nd blood without inducing thrombus formation.7 Cur-
ently, we have developed a thrombin-free fibrin-coated
mall-caliber vascular prosthesis.8 Although conventional
brin coatings in vascular grafts were composed of fibrin-
gen and thrombin, our fibrin coating was produced by the
onversion of fibrinogen without additional thrombin. We
ocumented that the 2-mm thrombin-free fibrin-coated vas-
ular prostheses with xenologous fibrin had a good perfor-
ance of antithrombogenicity with a patency rate of 100%
fter 2 months.
However, it is generally accepted that the recipient re-
ction due to immunologic response is one reason for graft
ioincompatibility after the implantation of vascular pros-
heses.9,10 Activation of the immune system has been indi-
ated as a further factor involved in the graft patency of
ascular prostheses. On the other hand, autologous blood
onation is generally effective in preventing adverse effects
f allogeneic blood donation, including immunologic re-
ponse.11 Therefore, we hypothesized that autologous, com-
ared with xenologous, fibrin coating in small-caliber vas-
ular grafts could suppress the immunologic response and
Abbreviations and Acronyms
ACD  acid-citrate-dextrose
A-graft  autologous fibrin-coated vascular
prostheses
ANOVA  analysis of variance
ELISA  enzyme-linked immunosorbent assay
ICAM-1  intercellular adhesion molecule-1
NCS  newborn calf serum
NFB  nuclear factor-kappa B
PAI-1  plasminogen activator inhibitor-1
PBS  phosphate-buffered saline
POD  postoperative day
SEM  scanning electron microscopic
tPA  tissue-type plasminogen activator
VCAM-1 vascular cell adhesion molecule-1
X-graft  xenologous fibrin-coated vascular
prosthesesmprove graft antithrombogenicity. The purpose of the n
The Journal of Thoracicresent study was to evaluate antithrombogenic and immu-
ologic responses associated with autologous fibrin coating
n our small-caliber vascular prostheses.
aterials and Methods
ifty Japanese white rabbits weighing 2.5 to 3.5 kg were used. The
andling of laboratory animals and their use in experiments con-
ormed to the Guidelines for Animal Experiment at Kobe Univer-
ity Graduate School of Medicine and the Guide for the Care and
se of Laboratory Animals published by the National Academy
ress.12
reparation of Vascular Prostheses
nitted polyester fabric vascular prostheses with an elastic spinal
uter reinforcer (internal diameter, 2 mm; water porosity, 4000
L/min/cm2 at 120 mm Hg; Terumo Co., Kanagawa, Japan) were
sed as a basic matrix and were coated with autologous fibrin
A-graft) or xenologous fibrin (X-graft) by a thrombin-free fibrin
oating technique.8 Briefly, 40 mL of blood with 8 mL of acid-
itrate-dextrose (ACD) anticoagulant solution was collected from
he rabbit itself for A-graft or from a human donor for X-graft.
fter centrifugation at 1000g for 20 minutes at 20°C, the plasma
as slowly incubated with an equal volume of hydroxyethyl-
iperazineethane sulfonic acid buffered saline solution (HEPES
uffer, pH 7.4) containing 16% ethanol and shaken for 1 hour at
°C to 4°C. After centrifugation at 1000g for 20 minutes at 4°C,
he supernatant was removed and the precipitate was dissolved
n HEPES buffer (pH 7.4) with a fibrinogen concentration of 20
g/mL. The fibrinogen solution was gently mixed with a solu-
ion containing 9 mmol/L CaCl2, 103 mmol/L NaCl, 4 mmol/L
Cl, and 28 mmol/L sodium lactate for a polymerization of
brin. Before the fibrin polymerization, the fibrin solution was
mmediately applied to the knitted polyester fabric vascular
rosthesis by injection under pressure. The graft was coated
ith the polymerized fibrin within 10 minutes. The graft was
ir-dried for 30 minutes at 25°C. There was no difference in the graft
reparation between A-grafts and X-grafts. The thrombin-free
brin-coated vascular grafts were sterilely preserved at 4°C until
raft implantation.
raft Implantation
nimals were anesthetized with an initial intravenous dose of 20
g/kg of pentobarbital sodium. Additional local anesthesia, con-
aining 1% lidocaine, was applied in the cervical portion. Using a
terile technique, A-grafts and/or X-grafts (length, 2.5 cm) were
mplanted in bilateral common carotid arteries as described previ-
usly.8 Neither antiplatelet nor anticoagulant therapy was admin-
stered after graft implantation.
We evaluated both A-grafts and X-grafts in different groups,
hich were divided by the selection of implanted grafts in the
ndividual rabbit as follows. In group I, animals (n  40) had a
ifferent graft—A-graft and X-graft—on each side. In the identi-
al animal, both grafts were compared for graft patency, histology,
nd thrombotic, inflammatory, and immunologic responses at 1, 3,
, 10, 14, 30, 60, and 180 days after implantation (5 animals in
ach end point). In group II, animals had the same graft—A-graft
nd A-graft (group IIa, n  5) or X-graft and X-graft (group IIx,
 5)—on both sides. In both subgroups, systemic thrombotic,
and Cardiovascular Surgery ● Volume 133, Number 5 1269
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1
ETnflammatory, and immunologic responses were evaluated before
raft implantation and 1, 3, 7, 10, 14, 30, 60, and 180 days after
mplantation by using serial blood samples.
raft Explantation
n group I, grafts were explanted at each end point under the same
eneral anesthesia as that of graft implantation. Before explanta-
ion, blood samples were collected and the graft patency was
xamined in the graft and distal artery. After heparin sodium (200
U/kg) was administrated intravenously to prevent clotting, grafts
ere explanted and gently flushed with normal saline solution to
emove any external blood. Animals were killed with a lethal dose
f intravenous potassium chloride. After explantation, the graft
as evaluated on platelet deposition and then cut into two longi-
udinal halves. One specimen was evaluated for graft histology,
mmunohistochemistry, and scanning electron microscopic (SEM)
xamination, and the other specimen was used to detect anti-graft
ntibodies by enzyme immunoassay.
icroscopic Evaluation
pecimens were fixed in 10% formaldehyde, embedded in paraf-
n, and cut along the longitudinal axis. Hematoxylin-eosin (HE)
nd immunohistochemical stains were obtained. The neointimal
yperplasia was quantified near the proximal anastomosis and at
he center of the graft with the NIH image program (version 1.63,
ational Institutes of Health, Bethesda, MD). The thickness of the
eointima was determined from the mean thickness at 5 longitu-
inal sections. Immunohistochemical stainings were performed
ith a Vectastain Elite ABC kit (Vector Laboratories, Burlingame,
A). Nuclei were counterstained with hematoxylin. As primary
ntibodies to evaluate inflammatory response in both grafts, mouse
nti-human intercellular adhesion molecule-1 (ICAM-1, Zymed
aboratories, South San Francisco, CA), vascular cell adhesion
olecule-1 (VCAM-1, Lab Vision, Fremont, CA), nuclear factor-
appa B (NFB, Lab Vision), and CD45 (Zymed Laboratories)
ere used. The number of CD45-positive cells was quantified by
ounting immunoreactive cells in 10 nonoverlapping high-power
elds. The luminal surfaces of the graft specimens were observed
ith SEM. Each specimen was fixed with 1% glutaraldehyde and
rocessed by postfixation in 1% osmium tetroxide, freeze-dried,
nd sputter-coated with platinum.
adiolabeling of Platelets and Quantification of
raft Platelet Deposition
wenty-four hours before graft harvest, autologous platelets were
abeled with radioactive 111Indium (In) and reinjected intrave-
ously, as previously described.8,13 Briefly, autologous platelets
ere incubated with 10 to 37 MBq of 111In-oxyquinoline solution
Amersham International, Buckinghamshire, UK) for 10 minutes
t 37°C. After centrifugation (1000g for 10 minutes), the pellet
as resuspended in 5 mL of normal saline/ACD solution and
einjected into the ear vein of a rabbit. The mean labeling effi-
iency was 86.4%  5.2%. After the grafts were explanted,
11In-labeled platelet deposition of the graft was measured imme-
iately by a gamma well counter (1470 WIZARD; Wallac, Turku,
inland). Graft radioactivity was expressed as counts per minute.
otal platelet deposition of the graft was normalized to graft
urface area and number of 111In-labeled platelets. s
270 The Journal of Thoracic and Cardiovascular Surgery ● Maetection of Anti-graft Antibodies by
nzyme Immunoassay
nti-graft antibodies, defined as immunoglobulin (Ig) G antibodies
gainst the implanted vascular prostheses, were detected by a previ-
usly described enzyme-linked immunosorbent assay (ELISA)
ith modifications.14 Briefly, a segment (length, 5 mm) of each
raft specimen was placed into polystyrene tube (low binding
apacity) with phosphate-buffered saline (PBS; pH 7.4) containing
0% newborn calf serum (NCS) for 16 hours at 4°C to block
onspecific binding (1 mL/tube). After 4 washes with PBS con-
aining 0.05% Tween 20 (PBST), each plasma sample diluted
/100 in PBST/NCS was added into the tube (500 L/tube) and
ncubated with shaking for 1 hour at room temperature. After 6
ashes, bound IgG on the graft segment was detected by incuba-
ion with shaking for 1 hour at room temperature with horseradish
eroxidase-conjugated goat anti-rabbit IgG (Fc-specific; Chemicon
nternational, Temecula, CA, USA) diluted 1/5000 in PBST/NCS
500 L/tube). After another 6 washes, chromogenic substrate solu-
ion containing 3.7 mmol o-phenylenediamine dihydrochloride
Wako Pure Chemical Industries, Osaka, Japan) and 0.012% H2O2
n hydrogenphosphate (85 mmol/L)/citric acid (35 mmol/L) buffer
pH 5.5) were added (100 L/tube). After 0.5 hours of incubation
n the dark, the reaction was stopped by 4 mol/L H2SO4 (500
L/tube), and each sample was transferred into 96-well microtiter
lates. Optical density was measured at 490 nm (OD490) on the
odel 550 microplate reader (Bio-Rad Laboratories, Hercules,
A, USA).
iochemical Analyses by Enzyme Immunoassay
n group II, serum levels of IgM, IgG, interleukin-1  (IL-1),
issue-type plasminogen activator (tPA), and plasminogen activa-
or inhibitor-1 (PAI-1) were serially measured by ELISA. All
lood samples were collected via an ear vein and centrifuged
mmediately. The plasma was frozen and stored until biochemical
nalyses were performed. Commercial kits for IgG, IgM (Bethyl
aboratories, Montgomery, TX), IL-1 (BioSource, International,
amarillo, CA), tPA, and PAI-1 (Biopool International, Ventura,
A)15 were used for the analyses. The tPA/PAI-1 ratio was cal-
ulated to provide insights about the relative fibrinolytic “balance”
n each subgroup.
tatistical Analysis
atabase management and statistical analysis were performed with
he Statview (Version 5.0) software package (Abacus Concepts
nc, Berkeley, CA). All values are expressed as the means 
tandard deviation (SD). In group I, comparisons between both
rafts were performed with Student t test. In group II, serial
hanges of serum biochemical levels in both subgroups were
ompared by a repeated-measures analysis of variance (ANOVA).
imple linear regression analysis was performed by the least
quares method to determine the relationship between serum bio-
hemical level and platelet deposition in both grafts.
esults
raft Patency and Appearance
oth A-grafts and X-grafts were patent without macro-copic thrombus or stenosis at each end point of graft
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ETxplantation throughout the 180 days of follow-up. The
istologic findings indicate that the fibrin coating in both
rafts started to be absorbed gradually after graft implanta-
ion and was completely degraded and replaced with neo-
brin net between postoperative day (POD) 7 and POD 14.
uring this period, the inflammatory response with full-wall
ellular infiltration in A-grafts was observed to be less
evere than that in X-grafts. Immunohistochemical studies
ndicated that the expressions of ICAM-1, VCAM-1, and c
The Journal of ThoracicFB in A-grafts were less than those in X-grafts. There
ere also significantly fewer CD45-positive cells in A-
rafts than those in X-grafts (74  16 vs 233  35 cells per
igh power field, P  .0001, Figure 1). SEM studies on
OD 10 revealed that the adhesion of activated platelets on
he luminal surface in A-grafts was less than that in X-grafts
t each point of graft explantation (Figure E1). After POD
4, neointimal formation on the luminal surface and small-
Figure 1. Immunohistochemistry. (Left)
Autologous fibrin-coated vascular pros-
theses (A-graft). (Right) Xenologous
fibrin-coated vascular prostheses (X-
graft). A, B, ICAM-1; C, D, VCAM-1; E,
F, NFB (original magnifications 20);
G, H, CD45 (original magnifications
40). Note the decrease in I-CAM-1,
VCAM-1, NFB, and CD45 expression
in A-grafts.apillary formation arising from the surrounding connective
and Cardiovascular Surgery ● Volume 133, Number 5 1271
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1
ETissues were observed in both grafts. At POD 180, the
eointima in A-grafts was significantly thinner than those in
-grafts (50.9  12.8 vs 237.6  23.4 m at the anasto-
osis site, 26.3  9.2 vs 168.4  21.7 m at the central
ite, P  .0001, respectively, Figure 2).
uantification of Platelet Deposition
11In-labeled platelet scintigraphy results in group I are
hown in Figure 3. In both grafts, a very low amount of
latelets was deposited on the graft until POD 3. However,
fter that, the platelet deposition increased steeply and
eached a maximal level on POD 10. The maximal platelet
epositions in A-grafts were 10.3  1.6  106/mm2,
hereas those in X-grafts were 17.4  1.4  106/mm2. A
arge amount of platelets were deposited on the graft until
OD 14, and then the platelet deposition decreased gradu-
lly. Platelet deposition in A-grafts was significantly less
han that in X-grafts until POD 30 (POD 1, 3, 7, 10, and 14,
espectively, P  .01; POD 30, P  .029).
0
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* *
*
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Days after graft implantation
P
la
te
le
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(106/mm2)
1 3 7 1410 30 60 180
A-graft
X-graft
*
igure 3. Platelet deposition. Platelet deposition in autologous
brin-coated vascular prostheses was significantly less than that
n xenologous fibrin-coated vascular prostheses until postopera-Pive day 30. Values are given as mean  SD. *P < .05.
272 The Journal of Thoracic and Cardiovascular Surgery ● Manti-graft Antibody Formation
nti-graft antibodies against A-grafts and X-grafts after
mplantation were sensitively detected in group I. In both
rafts, anti-graft antibody elevated to the peak on POD 1
uickly and then decreased gradually. The maximal level of
nti-graft antibody in A-grafts was 0.17  0.02 OD490,
hereas that in X-grafts was 0.46  0.06 OD490. Anti-graft
ntibodies in A-grafts remained at low levels at every point
f the study protocol and were significantly less than those
n X-grafts until POD 30 (POD 1, 3, 7, and 10, respectively,
 .001; POD 14 and 30, respectively, P  .01).
erial Changes of Serum IgM, IgG, IL-1,
PA, and PAI-1
n both subgroups, serum IgM levels increased sharply to a
eak on POD 3 and then decreased quickly, whereas serum
gG levels increased to a peak on POD 10 and decreased
radually. However, serum IgM and IgG levels in group IIa
ere quite low at every point and were significantly less than
hose in group IIx throughout the 180 days of follow-up (by
NOVA, P  .0001, respectively, Figure 4). On POD 10,
erum IL-1 in group IIa reached the maximal level of
00.3  27.0 pg/mL, whereas it was 882.8  102.2 pg/mL
n group IIx. Serum IL-1 levels in group IIa were low at
very point and significantly less than those in group IIx
hroughout the 180 days of follow-up (by ANOVA, P 
0001). There was no statistically significant difference in
he serial change of serum PAI-1 between both subgroups,
hereas serum tPA level in group IIa was significantly less
han that in group IIx (by ANOVA, P  .0001). The mean
aseline of tPA/PAI-1 ratio before graft implantation was
.26  0.08. Compared with the baseline, the tPA/PAI-1
atios in both subgroups increased after graft implantation
nd reached a peak on POD 10. The tPA/PAI-1 ratio in
roup IIa was significantly less than that in group IIx (by
NOVA, P  .0001, Figure 5).
orrelations of Serum IgG Level and tPA/PAI-1 Ratio
ith Platelet Deposition
imple linear regression analyses of serum IgG level, tPA/
Figure 2. Neointimal hyperplasia at
anastomosis site. HE stain (original mag-
nification 20). A, Autologous fibrin-
coated vascular prostheses. B, Xenolo-
gous fibrin-coated vascular prostheses.
Note the significant decrease in neo-
intimal thickness (arrows) in A-grafts.AI-1 ratio, and platelet deposition are illustrated in Figure 6.
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ETerum IgG level correlated significantly with platelet dep-
sition in both A-grafts (P  .0001, r  .698) and X-grafts
P  .0001, r  .725), and tPA/PAI-1 ratio correlated
ignificantly with platelet deposition in both A-grafts (P 
0001, r  .850) and X-grafts (P  .0001, r  .839).
0
100
200
300
Ig
G
/ I
gM
(n
g/
m
L
)
*
**
Days after graft implantation
pre 1 3 7 10 14 30 60 180
Group IIa : IgG, 
Group IIx : IgG, IgM
IgM
igure 4. Serum levels of IgM and IgG. Serial changes of serum
gM and IgG levels in autologous fibrin-coated vascular prosthe-
es (group IIa) were significantly less than those in xenologous
brin-coated vascular prostheses (group IIx). Values are given as
ean  SD. *P < .05 (ANOVA) in IgG; **P < .05 (ANOVA) in IgM.
igure 5. Serum levels of tPA/PAI-1 ratio. The tPA/PAI-1 ratio in
utologous fibrin-coated vascular prostheses (group IIa) was
ignificantly less than those in xenologous fibrin-coated vascular
rostheses (group IIx). Values are given as mean  SD. *P < .05.ANOVA).
The Journal of Thoraciciscussion
ur 2-mm vascular prostheses with fibrin coating showed
igh antithrombogenicity in the present study. The patency
f both autologous fibrin-coated vascular prostheses (A-
rafts) and xenologous fibrin-coated vascular prostheses
X-grafts) was 100% at each end point of graft explanta-
ion throughout the 6 months of follow-up. There were
everal reports of 2-mm small-caliber vascular prostheses
n the rabbit model previously,16-19 but their longest patency
as 100% at 2 months after implantation in expanded
olytetrafluoroethylene grafts.17 Although our results
hould be assessed with some considerations concerning
nimal species– dependent thrombogenicity, the graft pal-
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igure 6. Correlations of serum IgG level and tPA/PAI-1 ratio with
latelet deposition. Serum IgG level and tPA/PAI-1 ratio corre-
ated significantly with platelet deposition in both grafts (P <
0001, respectively).
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1
ETency of our 2-mm vascular prostheses with fibrin coating
as satisfactory. Thrombin-free fibrin-coated vascular pros-
heses, about which we have previously reported,8 have a
reatly improved antithrombogenicity.
A literature review revealed two reports of a coating of
ascular prostheses with autologous fibrin. Kjaergard and
eis-Fogh20 described the coating technique of autologous
brin in high-porosity double-velour vascular prostheses
5 mm in circumference, 4 cm in length). Cardon and
ssociates21 studied knitted polyester vascular prostheses
ith autologous fibrin coating (6 mm in diameter, 10 to 12
m in length) by porcine aortoiliac bypass model. The graft
atency in that study was 80% at 14 days and 55.5% at 90
ays. Their techniques of fibrin coating in vascular prosthe-
es were conventional in that fibrin was produced by fibrin-
gen and thrombin. Neither report evaluated the immuno-
ogic response of their autologous fibrin-coated vascular
rostheses.
After the implantation of vascular prostheses, cellular
mmunologic response, which is mediated by T lympho-
ytes and macrophages, plays a central role in the acute
nflammatory process.9,10,22 In the present study, a smaller
umber of these CD45-positive cells infiltrated into A-grafts
han into X-grafts. ICAM-1, VCAM-1, and NFB expres-
ion in A-grafts decreased after graft implantation, com-
ared with those of X-grafts. Moreover, serum IL-1 levels
n A-grafts were significantly less than those in X-grafts
hroughout 180 days after graft implantation. These results
uggest that the autologous fibrin coating suppresses the
nflammatory reaction in vascular prostheses. On the other
and, it is still controversial whether the antibody formation
nduced by humoral immune response is important for the
nflammatory process. Recently, Schlosser and col-
eagues14,23 demonstrated the immunogenicity of implanted
olyester vascular prostheses with the formation of specific
umoral antibodies. They insisted that humoral immune
esponse against implanted components may provide a po-
ential marker that facilitates monitoring of the individual
erigraft reaction and the graft biocompatibility. In the
resent study, the measurement of anti-graft antibodies was
seful to evaluate the immunogenicity of A-grafts and X-
rafts themselves. Anti-graft antibodies in A-grafts re-
ained at quite low levels at every point of the study
rotocol throughout the 180 days of follow-up and was
ignificantly less than the levels in X-grafts until POD 30.
It is well known that normal individuals have natural
ntibodies that react with a wide variety of antigens in the
bsence of any evidence of prior exposure. These antibodies
re low levels of circulating IgM and IgG antibodies and
eact systemically not only with infections agents but also
ith antigens expressed on unrelated tissues.24,25 There
ere many studies for natural antibodies in the field of
enografts, and it was revealed that transplantation of un- t
274 The Journal of Thoracic and Cardiovascular Surgery ● Maelated tissues induces a rapid increase of serum IgM and a
ubsequent increase of serum IgG.26,27 Similar results were
bserved in serum IgM and IgG levels after implantation of
-grafts in this study. We thought that xenologous fibrin
oating of vascular prostheses reacted with natural antibod-
es as antigens expressed on unrelated tissues. On the other
and, serum IgM and IgG in A-grafts remained at low
evels after graft implantation. Interestingly, there was close
orrelation between platelet deposition and serum IgG level
n both grafts. Recently, Colvin and Smith28 reported that
ntibodies induce graft rejection acutely through the fixation
f a complement, resulting in tissue injury and coagulation.
ur findings support the view that that immunologic re-
ponse after graft implantation has an effect on graft
hrombogenicity.
Our thrombin-free fibrin-coated vascular prostheses had
tendency to increase platelet deposition between PODs 7
nd 14. Because fibrin coating was degraded during this
eriod, we thought that the increase of platelet deposition
as caused by the shearing effect of blood according to the
egradation of fibrin coating.8 However, platelet deposition
n A-grafts during the period was approximately 60% of that
n X-grafts in the present study and remained at low levels
uring the 6 months of follow-up, with a significant de-
rease until POD 30. This result strongly suggests that
utologous fibrin-coated vascular prostheses have high an-
ithrombogenicity. Previously, we have investigated another
brin-coated vascular prosthesis with thrombin (internal
iameter, 3 mm) in coronary artery bypass grafting in a
heep model.29 We proved that a large amount of platelets
as deposited on the graft surface between PODs 7 and 14
nd that the grafts were occluded by thrombus during this
eriod. We believe that it is very important to improve graft
ntithrombogenicity, especially between PODs 7 and 14, for
successful development of our fibrin-coated vascular
rostheses.
In this study, A-grafts induced a decrease in serum tPA
ctivity without affecting serum PAI-1 activity and im-
roved the fibrinolytic balance of tPA/PAI-1 compared with
-grafts. Interestingly, there was a significantly positive
orrelation between tPA/PAI-1 ratio and platelet deposition
n both grafts. We supposed that the decrease of platelet
eposition on graft surface in A-grafts may reduce serum
PA activity, leading to adequate lysis of thrombi, following
he improvement of fibrinolytic balance.
Knowing how long the fibrin coating lasts is crucial to
stimate the long-term results of our fibrin-coated vascular
rostheses. Along with degradation, the fibrin coating was
ompletely replaced with a neofibrin net that migrated from
lood circulation in the rabbit itself by POD 14 in both
rafts.8 The neofibrin net consists of autologous fibrin,
hich means the autologous fibrin coating would last morehan 14 days after implantation. Although we do not have
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ETny data as to how long the neofibrin net lasts in the grafts,
e believe that the autologous fibrin coating followed by
he neofibrin net induces the excellent graft antithromboge-
icity. Further study of the degradation of fibrin coating is
eeded. There are also inevitable questions whether the
eofibrin is the same in both grafts and whether the immu-
ologic responses against them since POD 14 are the same
n both grafts. Although the nature of antigens in vascular
rostheses is not yet known, Rubin and Matron30 recently
roved that human fibrinogen induces cross-reactive immu-
ity to mouse fibrinogen in a mouse model with human
brinogen injected subcutaneously. It is possible that xe-
ologous fibrin in vascular prostheses might induce cross-
eactive immune response to the neofibrin net of rabbits in
his study. Therefore, humoral immune response, inflamma-
ory response, and fibrinolytic imbalance as well as platelet
eposition in X-grafts may be kept longer than those in
-grafts after the replacement of fibrin coating. The long-
tanding nature of these responses to graft injury may cause
eointimal hyperplasia in X-grafts. Further study of the
ature of antigens in fibrin-coated vascular prostheses is
eeded.
In addition to reduced immunologic response and throm-
ogenicity, it is generally agreed that coating with autolo-
ous fibrin has 2 more advantages: promotion of graft
ealing and elimination of the risk of viral transmission.11,21
n this study, 1 layer of endothelial-like cells was evident on
OD 60 in A-grafts and on POD 180 in X-grafts. Although
he presence of these cells was not demonstrated by a
ypical endothelial cell staining such as von Willebrand
actor (data not shown), Cardon and associates21 supposed
hat autologous fibrin matrixes could serve as supports for
ther molecules such as growth factors or cell material to
ccelerate endothelialization. Although there was no differ-
nce of graft patency between A-grafts and X-grafts in the
resent study, those advantages of autologous fibrin may
esult in less neointimal hyperplasia of A-grafts on POD
80.
Our technique can provide a sufficient quality of fibrin
oating in vascular prostheses within approximately 3
ours. Although rabbit blood was collected more than 1
onth before graft implantation, according to animal care
egulations, in this study, human blood can be collected
mmediately before graft preparation. In addition, we have
hecked that the experimental grafts were able to be pre-
erved in a sterile condition for at least 6 months. Therefore,
ur technique can be used in both elective and emergency
urgery in clinical settings.
The limitation of this study is that an immunologic
eaction of the blood in group I might have had a negative
epercussion on both grafts because all rabbits in group I
ere implanted with X-graft. However, we were afraid thatndividual differences could affect the results of local reac-
The Journal of Thoracicion in implanted grafts, such as graft patency, graft appear-
nce, platelet deposition, and anti-graft antibody formation.
n consideration of the negative repercussions, systemic
erum reactions in both grafts were evaluated in group II.
In conclusion, autologous fibrin-coated vascular prosthe-
es had less thrombogenicity and reduced immunologic
esponse compared with those of xenologous fibrin-coated
ascular prostheses. Moreover, there was a close correlation
etween platelet deposition and serum IgG levels in vascu-
ar prostheses. These results strongly support our hypothesis
hat autologous fibrin coating can improve antithromboge-
icity by reducing immunologic response. Autologous
hrombin-free fibrin-coated vascular prostheses have a po-
ential for clinical use in hybrid small-caliber vascular
rafts.
This work was supported in part by a Grant-in-Aid for Scien-
ific Research (C) (No. 15591473) from the Japan Society for the
romotion of Science and a research grant from Mitsubishi
harma Research Foundation.
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ETFigure E1. Scanning electron micrographs of the luminal surface on postoperative day 10 (original magnification
2500). A, Autologous fibrin-coated vascular prostheses. B, Xenologous fibrin-coated vascular prostheses. Acti-
vated platelets were adhered to and formed aggregates on the luminal surface in both grafts. The platelet adhesion
in A-grafts was less than that in X-grafts.The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1276.e1
